Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Factor XI LICA to Reduce Thrombotic Events in End-Stage Renal Disease Patients on Hemodialysis
2019-003927-39Phase 2Completed
- Sponsor
- Bayer
- Start
- May 2020
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in end-stage kidney disease (ESKD) comparing BAY 2976217 with Placebo (2 arms). Primary endpoint: Major and clinically-relevant non-major bleeding. Started May 2020; status: completed.
02
Drugs
fesomersen
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2019-003927-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003927-39.